Literature DB >> 12897209

Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease.

Alon Monsonego1, Victor Zota, Arnon Karni, Jeffery I Krieger, Amit Bar-Or, Gal Bitan, Andrew E Budson, Reisa Sperling, Dennis J Selkoe, Howard L Weiner.   

Abstract

Alzheimer disease (AD) is characterized by the progressive deposition of the 42-residue amyloid beta protein (Abeta) in brain regions serving memory and cognition. In animal models of AD, immunization with Abeta results in the clearance of Abeta deposits from the brain. However, a trial of vaccination with synthetic human Abeta1-42 in AD resulted in the development of meningoencephalitis in some patients. We measured cellular immune responses to Abeta in middle-aged and elderly healthy subjects and in patients with AD. A significantly higher proportion of healthy elderly subjects and patients with AD had strong Abeta-reactive T cell responses than occurred in middle-aged adults. The immunodominant Abeta epitopes in humans resided in amino acids 16-33. Epitope mapping enabled the identification of MHC/T cell receptor (TCR) contact residues. The occurrence of intrinsic T cell reactivity to the self-antigen Abeta in humans has implications for the design of Abeta vaccines, may itself be linked to AD susceptibility and course, and appears to be associated with the aging process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897209      PMCID: PMC166296          DOI: 10.1172/JCI18104

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Cerebral hemorrhage after passive anti-Abeta immunotherapy.

Authors:  M Pfeifer; S Boncristiano; L Bondolfi; A Stalder; T Deller; M Staufenbiel; P M Mathews; M Jucker
Journal:  Science       Date:  2002-11-15       Impact factor: 47.728

2.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

3.  Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease.

Authors:  B Urbanc; L Cruz; R Le; J Sanders; K Hsiao Ashe; K Duff; H E Stanley; M C Irizarry; B T Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-09       Impact factor: 11.205

4.  Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro.

Authors:  L F Lue; R Rydel; E F Brigham; L B Yang; H Hampel; G M Murphy; L Brachova; S D Yan; D G Walker; Y Shen; J Rogers
Journal:  Glia       Date:  2001-07       Impact factor: 7.452

5.  Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro.

Authors:  Jürgen Haas; Brigitte Storch-Hagenlocher; Annette Biessmann; Brigitte Wildemann
Journal:  Neurosci Lett       Date:  2002-04-05       Impact factor: 3.046

6.  Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases.

Authors:  Takashi Togo; Haruhiko Akiyama; Eizo Iseki; Hiromi Kondo; Kenji Ikeda; Masanori Kato; Tatsuro Oda; Kuniaki Tsuchiya; Kenji Kosaka
Journal:  J Neuroimmunol       Date:  2002-03       Impact factor: 3.478

Review 7.  Antigenic mimicry, clonal selection and autoimmunity.

Authors:  I R Cohen
Journal:  J Autoimmun       Date:  2001-05       Impact factor: 7.094

8.  Generation of CD4(+)CD25(+) regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression.

Authors:  Kimito Kawahata; Yoshikata Misaki; Michiko Yamauchi; Shinji Tsunekawa; Keigo Setoguchi; Jun-ichi Miyazaki; Kazuhiko Yamamoto
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

9.  Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice.

Authors:  Roberto Furlan; Elena Brambilla; Francesca Sanvito; Luca Roccatagliata; Stefano Olivieri; Alessandra Bergami; Stefano Pluchino; Antonio Uccelli; Giancarlo Comi; Gianvito Martino
Journal:  Brain       Date:  2003-02       Impact factor: 13.501

10.  Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node.

Authors:  Clemens Scheinecker; Rebecca McHugh; Ethan M Shevach; Ronald N Germain
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more
  118 in total

1.  Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity.

Authors:  Sue Stacy; Earlanda L Williams; Nathan E Standifer; Amanda Pasquali; Keith A Krolick; Anthony J Infante; Ellen Kraig
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

2.  CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.

Authors:  Sungho Lee; Nicholas H Varvel; Megan E Konerth; Guixiang Xu; Astrid E Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

3.  Microglial TNF-α-dependent elevation of MHC class I expression on brain endothelium induced by amyloid-beta promotes T cell transendothelial migration.

Authors:  Yi-Ming Yang; De-Shu Shang; Wei-Dong Zhao; Wen-Gang Fang; Yu-Hua Chen
Journal:  Neurochem Res       Date:  2013-08-29       Impact factor: 3.996

4.  Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.

Authors:  Marybeth Camboni; Chiou-Miin Wang; Carlos Miranda; Jung Hae Yoon; Rui Xu; Deborah Zygmunt; Brian K Kaspar; Paul T Martin
Journal:  Neurobiol Dis       Date:  2013-09-08       Impact factor: 5.996

Review 5.  T-cells in Alzheimer's disease.

Authors:  Terrence Town; Jun Tan; Richard A Flavell; Mike Mullan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 6.  Immune shaping and the development of Alzheimer's disease vaccines.

Authors:  Howard J Federoff; William J Bowers
Journal:  Sci Aging Knowledge Environ       Date:  2005-11-16

7.  Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.

Authors:  Bao-Xi Qu; Qun Xiang; Liping Li; Stephen Albert Johnston; Linda S Hynan; Roger N Rosenberg
Journal:  J Neurol Sci       Date:  2007-06-15       Impact factor: 3.181

8.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

Review 9.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

10.  An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

Authors:  Einar M Sigurdsson; Elin Knudsen; Ayodeji Asuni; Cheryl Fitzer-Attas; Daniel Sage; David Quartermain; Fernando Goni; Blas Frangione; Thomas Wisniewski
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.